Clinical Trial

A Study of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including HCC

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This is a multicenter, open-label, Phase 1, first-in-human, dose-escalation study designed to assess the safety, tolerability and define the RP2D of MT-303 alone (Module 1) and in combination with Atezo/Bev (Module 2) in participants with advanced hepatocellular carcinoma expressing GPC3.
Protocol Amendment History 6 amendments
This ClinicalTrials.gov record has been amended 6 times since 2024-06-24; most recent amendment 2025-12-11.
Status change: Not Yet Recruiting → Recruiting 2024-06-27
Trial Details
NCT Number NCT06478693
Lead Sponsor Myeloid Therapeutics
Collaborators: CREATE Medicines
Conditions Hepatocellular Carcinoma
Enrollment 70 participants
Start Date 2024-07-01
Primary Completion 2027-12-31 (estimated)
Study Completion 2028-05-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-18